



26 AUG 2005  
UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450  
www.uspto.gov

Daniel M Chambers  
Biotechnology Law Group  
658 Marsolan Avenue  
Solana Beach CA 92075


In re Application of	:	DECISION ON
RUBASSAY	:	
Application No.: 10/516,757	:	PETITION UNDER
PCT No.: PCT/US03/09031	:	
Int. Filing Date: 25 March 2003	:	37 CFR 1.137(b)
Priority Date: 25 March 2002	:	
Attorney Docket No.: GTI-1490-USN	:	
For: MINIMIZING METAL TOXICITY	:	
DURING ELECTROPORATION ENHANCED	:	
DELIVERY OF POLYNUCLEOTIDES	:	

The petition to revive under 37 CFR 1.137(b) filed 04 December 2004 in the above-captioned application is hereby **GRANTED** as follows:

Applicant's statement that the "entire delay in filing the required reply from the due date for the reply until the filing of this petition under 37 CFR 1.137(b) was unintentional" meets the requirements of 37 CFR 1.137(b)(3).

A review of the application file reveals that the required petition fee of \$1370 was paid. Thus, the requirements of 37 CFR 1.137(b) have been satisfied. Therefore, the request to revive the application abandoned under 35 U.S.C. 371(d) is granted as to the National stage in the United States of America. The declaration in compliance with 37 CFR 1.497(a) and (b) has been provided and is acceptable.

This application is being forwarded to the United States Designated/Elected Office for further processing. The 35 U.S.C. 371(c)(1), (c)(2) and (c)(4) date is 04 December 2004.

  
Cynthia M. Kratz  
Attorney Advisor  
Office of PCT Legal Administration

Telephone: 571-272-3286  
Facsimile: 571-273-0459